SP
Surya Prakash
About Surya Prakash
Data last updated:
Surya Prakash is a Director at Nix Pharma Private Limited (since 2016) and Director at Emeric Pharma Private Limited (since 2022). The companies operate in Trading and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹5.2 Lakh; the largest is Nix Pharma Private Limited at ₹3.4 Lakh (FY 2017).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 16 Mar 2016 | 2011 | ₹3.4 Lakh (FY 2017) | Active | |
| Director | 05 Jan 2022 | 2022 | ₹1.8 Lakh (FY 2025) | Active |
Board colleagues of Surya Prakash
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ravi Prakash Srivastava | 07207547 | Nix Pharma Private Limited , Emeric Pharma Private Limited | Director |
| Shiv Bachan Singh | 05114450 | Nix Pharma Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Surya Prakash
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Surya Prakash
Surya Prakash currently holds 2 directorships: Nix Pharma Private Limited (Director, since 16 Mar 2016, revenue ₹3.4 Lakh (FY 2017)); Emeric Pharma Private Limited (Director, since 05 Jan 2022, revenue ₹1.8 Lakh (FY 2025)).
Surya Prakash was first appointed on 16 Mar 2016 as Director at Nix Pharma Private Limited. The most recent appointment on record is 05 Jan 2022 at Emeric Pharma Private Limited.
The 2 current companies of Surya Prakash that report revenue have a combined latest revenue of ₹5.2 Lakh: Nix Pharma Private Limited ₹3.4 Lakh (FY 2017); Emeric Pharma Private Limited ₹1.8 Lakh (FY 2025).
The current boards of Surya Prakash's companies include Ravi Prakash Srivastava (Nix Pharma Private Limited), Shiv Bachan Singh (Nix Pharma Private Limited).